COVID-19 Clinical Trial Resumptions Slow as Cases Rise Again
Clinical trials disrupted by COVID-19 are expected to resume at a much slower rate than originally anticipated, as more nations are re-enforcing lockdown due to a globally rising number of COVID-19 cases, says GlobalData.
Priya Nair, Trials Intelligence Analyst at GlobalData, commented, “The general trend shows a gradual increase in the overall percentage of trials for each trial status*, the biggest of which has been seen in trials that are ongoing and recruiting and those that are ongoing but not recruiting. Between August 17th and September 21st, ongoing and recruiting trials decreased from 84.7% to 82.2%, while completed trials increased from 4.5% to 6.4%.”
There is also an overall steady increase of trials resuming activity. The U.S. has the highest number of resumed trials at 70.6%, followed by France at 7.6%, the UK and Spain at 7%.
* Completed; Ongoing, not recruiting; Ongoing, recruiting; Planned
For more of their findings, click here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
